Neonatal hypoxic-ischaemic encephalopathy
Conditions
Brief summary
Occurrence of clinical or paraclinical adverse events during the child's follow-up (short- and long-term), attributable to the injected cell preparation, Feasibility of the study: percentage of children included for whom the cell therapy procedure could be completed according to the required quality criteria.
Detailed description
- Preliminary efficacy as measured by neurodevelopmental function till 2 years
Interventions
DRUGAutologous cord blood-derived viable nuclear cells 50E6/kg prep
Sponsors
Centre Hospitalier Regional De Marseille
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of clinical or paraclinical adverse events during the child's follow-up (short- and long-term), attributable to the injected cell preparation, Feasibility of the study: percentage of children included for whom the cell therapy procedure could be completed according to the required quality criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Preliminary efficacy as measured by neurodevelopmental function till 2 years | — |
Countries
France
Outcome results
None listed